Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Lymphoma, Non-Hodgkin 12Leukemia, Myeloid, Acute 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Lymphocytic, Chronic, B-Cell 9Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 7Lymphoma 7Glioblastoma 7Hodgkin Disease 6Burkitt Lymphoma 6Prostatic Neoplasms 5Recurrence 4Lymphoma, B-Cell, Marginal Zone 4Leukemia 4Hematologic Neoplasms 4Breast Neoplasms 4Waldenstrom Macroglobulinemia 3Triple Negative Breast Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Melanoma 3Lymphoma, Large-Cell, Anaplastic 3Glioma 3Astrocytoma 3Sezary Syndrome 2Sarcoma, Synovial 2

Interventions

Cisplatin 13Etoposide 11Paclitaxel 8Cyclophosphamide 7Carboplatin 7Ifosfamide 6etoposide phosphate 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5pembrolizumab 4fludarabine 4Sirolimus 4Bleomycin 4fludarabine phosphate 3Sunitinib 3Oxaliplatin 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bevacizumab 3Automobiles 3130-nm albumin-bound paclitaxel 3tremelimumab 2sodium thiosulfate 2ribociclib 2pralsetinib 2pegfilgrastim 2lutetium Lu 177 dotatate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Germ Cell and Embryonal × Leukapheresis × Clear all
NCT01505569 2024-02-26

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Masonic Cancer Center, University of Minnesota

Phase NA Completed
44 enrolled
CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Brain Neoplasms, Carcinoma, Renal Cell, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡